1 January 2017 in Journal of Korean Medical Science
Kim HY, et al. J Korean Med Sci. 2017 Oct;32(10):1633-1641. https://doi.org/10.3346/jkms.2017.32.10.1633
30 June 2022 in Annals of Pediatric Endocrinology & Metabolism
Purpose: Metabolically healthy overweight/obesity (MHO) and metabolically unhealthy overweight/obesity (MUO) are distinct clinical phenotypes classified by the presence of cardiometabolic risk factors in an individual. In the present study, we investigated temporal trends in the prevalence of MHO in Korean adolescents using nationally representative data.Methods: Data from the Korea National Health and Nutrition Examination Survey 2011–2019 were used in this study. A total of 5,667 adolescents (3,014 boys, 53.2%) aged 10–18 years was included in this study. MHO was defined as a body mass index ≥85th percentile for the corresponding age and sex and absence of any cardiometabolic risk factors.Results: The prevalence of overweight/obesity showed an increasing trend from 18.8% (boys 17.3% and girls 20.6%) in 2011 to 23.7% (boys 24.0% and girls 23.5%) in 2019 (p for trend=0.045). The overall prevalence of MHO during 2011–2019 was 39.2%, which was higher in girls than in boys (boys 33.5%, girls 46.2%, p<0.001), and the change in prevalence of MHO from 2011 to 2019 (from 34.8% to 35.7%) was not significant. Among MUO, the most prevalent cardiometabolic risk factor was dysglycemia (48.8%), followed by elevated blood pressure (41.5%), low high-density lipoprotein cholesterol (35.0%), and high triglycerides (29.7%).Conclusion: We observed a high prevalence of MHO in Korean youth with overweight/obesity. Although the prevalence of overweight/obesity increased, the prevalence of MHO was stable during 2011-2019. A risk-stratified approach based on metabolic health status can help reducing the medical and socioeconomic costs associated with obesity treatment.
30 June 2022 in Annals of Pediatric Endocrinology & Metabolism
Skeletal dysplasia is a diverse group of disorders that affect bone development and morphology. Currently, approximately 461 different genetic skeletal disorders have been identified, with over 430 causative genes. Among these, fibroblast growth factor receptor 3 (FGFR3)-related skeletal dysplasia is a relatively common subgroup of skeletal dysplasia. Pediatric endocrinologists may encounter a suspected case of skeletal dysplasia in their practice, especially when evaluating children with short stature. Early and accurate diagnosis of FGFR3-related skeletal dysplasia is essential for timely management of complications and genetic counseling. This review summarizes 5 representative and distinct entities of skeletal dysplasia caused by pathogenic variants in FGFR3 and discusses emerging therapies for FGFR3-related skeletal dysplasias.
1 January 2025 in Journal of Korean Medical Science
Kim HY, et al. J Korean Med Sci. 2025 Aug;40(41):e241. https://doi.org/10.3346/jkms.2025.40.e241
1 November 2022 in Annals of Laboratory Medicine
Hwa Young Kim, M.D., Ph.D., Choong Ho Shin, M.D., Ph.D., Young Ah Lee, M.D., Ph.D., Chang Ho Shin, M.D., Gu-Hwan Kim, Ph.D., and Jung Min Ko, M.D., Ph.D.. Ann Lab Med 2022;42:668-77. https://doi.org/10.3343/alm.2022.42.6.668
15 November 2025 in Clinical and Experimental Pediatrics
Continuous glucose monitoring (CGM) has become a key component in the management of pediatric type 1 diabetes mellitus (T1DM) since it offers real-time glucose data that facilitate tighter glycemic control and reduce acute complications. Accumulating evidence and international guidelines highlight the clinical efficacy, safety, and feasibility of CGM use in children, particularly those with high adherence. Regular CGM use is associated with significant reductions in glycated hemoglobin, fewer hypo- and hyperglycemia episodes, and improved quality of life for both patients and their caregivers. Recent advances in CGM technology—including improved accuracy, extended sensor wear, factory calibration, and customizable alerts—have enhanced their usability in pediatric populations. In addition to established CGM metrics such as time in range, time below range, and glycemic variability, a novel parameter—time in tight range (also referred as time in normoglycemia), defined as the percentage of time with blood glucose readings within 70–140 mg/dL—has emerged as a potentially more sensitive marker of optimal glycemic control in children. This review provides a comprehensive overview of CGM technologies, including device types, performance metrics, and clinical evidence supporting their use for pediatric T1DM. It also examines recent advancements in Korea such as expanded insurance reimbursement and clinical integration. As CGM becomes more accessible and technologically advanced, it is expected to play an increasingly central role in optimizing long-term outcomes for children and adolescents with T1DM.